MorphoSys Appoints New Supervisory Board Member
"We are very pleased that Dr. Colpan has joined our board", commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Dr. Colpan's experience in building QIAGEN into one of the world's leading biotechnology companies will be invaluable for MorphoSys to foster our new business initiative in the reagent field, Antibodies by Design."
Dr. Reinhardt joined the Supervisory Board of MorphoSys in July 2001 and refrained from seeking re-election due to increased other commitments. During his term with MorphoSys Dr. Reinhardt played a prominent role in the formulation of the Company's strategy.
"I want to thank Dr. Reinhardt for his invaluable support and commitment to MorphoSys during his term on our board. His expertise in drug development and extensive knowledge of the pharmaceutical industry have proved to be substantial assets. He has made an enormous contribution to the successful development of the Company", commented Dr. Moroney.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous